Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.

Metastatic Colorectal Cancer Clinical Trial

— AMELION  

Official title:

AMELION: A Randomized, Double Blinded, Phase 2, Efficacy and Safety Study of Abituzumab (EMD 525797) in Combination With Cetuximab and FOLFIRI Versus Placebo in Combination With Cetuximab and FOLFIRI in First-line RAS Wild-type, Left-sided, Metastatic Colorectal Cancer Patients With High ανβ6 Integrin Expression.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03688230
• Other study ID #: AP218797
• Secondary ID: 2018-003439-31AI
• Status: Withdrawn
• Phase: Phase 2
• Start date: April 2019
• Est. completion date: August 2021

Study information

• Verified date: March 2020
• Source: SFJ Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of the experimental drug abituzumab (EMD525797) in combination with cetuximab and FOLFIRI in RAS wild-type, left-sided, metastatic colorectal cancer patients with high ανβ6 integrin expression.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2021
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed and dated written informed consent prior to any study specific procedure;

2. Age: =18 years;

3. Evidence of newly diagnosed stage IV metastatic colorectal cancer. Primary tumor location on the left side of the Colon (including left splenic flexure) or rectum;

4. Demonstrated wild-type RAS mutation status in the tumor (primary tumor or metastasis) by local assessment;

5. Tumor tissue specimen shows high a?ß6 integrin expression, as determined by central laboratory assessment;

6. Tumor tissue specimen (formalin-fixed, paraffin-embedded block) preferably from primary resection and/or if available from a surgical sample from metastatic site must be available for central laboratory based a?ß6 integrin expression analysis. (No Fine Needle Aspiration [FNA] will be accepted);

7. At least 1 radiographically documented measurable lesion in a previously non-irradiated area according to RECIST (Version 1.1), i.e., this lesion must be adequately measurable in at least 1 dimension (longest diameter to be recorded) as =2 cm by conventional techniques or =1 cm by spiral CT scan;

8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1;

9. Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study;

Exclusion Criteria:

1. Demonstrated any RAS or BRAF mutation;

2. Prior anti-EGFR or other targeted therapy;

3. Prior chemotherapy of the colorectal cancer, except for (neo) adjuvant therapy completed at least 6 months before randomization;

4. Radiotherapy (localized radiotherapy for pain relief is allowed to non-target lesions);

5. Investigational drug treatment for the treatment of malignancies in the past;

6. Concurrent participation in another interventional clinical study;

7. Pregnancy (exclusion confirmed with beta-hCG test) or lactation;

8. Any history or evidence of brain metastases or leptomeningeal metastases;

9. History of secondary malignancy within the past 5 years, except for basal cell carcinoma or carcinoma in situ of the cervix uteri, if treated with curative intent;

10. Concomitant chronic systemic immune or hormone therapy not indicated in this study protocol (except for physiologic replacement; steroids up to 10 mg per day of prednisone equivalent or topical and inhaled steroids are allowed);

11. Clinically relevant coronary artery disease (New York Heart Association [NYHA] functional angina classification III/IV), congestive heart failure (NYHA III/IV), or clinically relevant cardiomyopathy;

12. Uncontrolled hypertension defined as systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg under resting conditions;

13. History of myocardial infarction in the last 12 months, or a high risk of uncontrolled arrhythmia, coagulation disorder associated with bleeding or recurrent thrombotic events, with the exception of arterial fibrillation treated with anti-coagulants;

14. Recent peptic ulcer disease (endoscopically proven) within 6 months of randomization, chronic inflammatory bowel disease, or acute/chronic ileus;

15. Active infection (requiring IV antibiotics and/or antiviral therapy), including active tuberculosis, active or chronic Hepatitis B or C, or ongoing HIV infection, AIDS;

16. Presence of any contra-indications or known hypersensitivity to treatment with abituzumab, cetuximab, and FOLFIRI, or to any of the excipients of these drugs;

17. Concomitant treatment with prohibited medications;

18. Medical or psychological conditions that would not permit the patient to complete the study.

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer

Intervention

Drug:
• abituzumab
1000 mg IV

Combination Product:
• Placebo + Cetuximab + FOLFIRI
400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min

Locations

Country	Name	City	State
n/a

Sponsors (5)

Lead Sponsor	Collaborator
SFJ Pharmaceuticals X, LTD.	Academic and Community Cancer Research United, AIO-Studien-gGmbH, Merck KGaA, Darmstadt, Germany, SFJ Pharmaceuticals, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS)	Progression free survival per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by investigator.	16 months
Secondary	Overall Survival (OS)	The overall survival is defined as the time from randomization to death from any cause.	68 months
Secondary	Objective Response Rate (ORR)	ORR will be estimated as the proportion of responders in each treatment arm, defined as a patient whose best overall response is PR or better during the treatment period according to RECIST 1.1.	16 months
Secondary	Depth of Response (DPR)	Depth of response will be estimated as the maximum percent tumor shrinkage during treatment.	16 months
Secondary	Early Tumor Shrinkage (ETS)	ETS will be estimated as the proportion of patients achieving a =20 % decrease from baseline in the sum of longest tumor diameters.	68 months
Secondary	Secondary Resection Rate With a Potentially Curative Intent	Patients for whom the resectability of metastases becomes evident during the study therapy should undergo a surgical resection of the metastases.	16 months
Secondary	Number of participants with treatment-related adverse events summarized by CTCAE severity grade (v5.0).	Adverse events will be summarized by body system, preferred term, severity, and relationship to treatment	68 months